BiotechTube

Lenvatinib 24 mg

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Thyroid Carcinoma, Anaplastic

Conditions

Thyroid Carcinoma, Anaplastic

Trial Timeline

Jul 7, 2016 → Sep 26, 2018

NCT ID
NCT02657369

About Lenvatinib 24 mg

Lenvatinib 24 mg is a phase 2 stage product being developed by Eisai for Thyroid Carcinoma, Anaplastic. The current trial status is terminated. This product is registered under clinical trial identifier NCT02657369. Target conditions include Thyroid Carcinoma, Anaplastic.

What happened to similar drugs?

20 of 20 similar drugs in Thyroid Carcinoma, Anaplastic were approved

Approved (20) Terminated (4) Active (0)
✅LenvatinibEisaiApproved
✅Cinacalcet HClKyowa KirinApproved
✅Growth hormone + Growth hormone treatment and pubertyEli LillyApproved
✅Paricalcitol + CalcifediolAbbVieApproved
✅Paricalcitol + Darbepoetin alfaAbbVieApproved
✅Alendronate 70mg weeklyMerckApproved
✅AMG 073AmgenApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02657369Phase 2Terminated

Competing Products

20 competing products in Thyroid Carcinoma, Anaplastic

See all competitors
ProductCompanyStageHype Score
MBX 2109MBX BiosciencesPhase 2
29
400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injectionMBX BiosciencesPhase 2
33
PCO371 + PlaceboChugai PharmaceuticalPhase 1
21
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
24
efatutazone + paclitaxelDaiichi SankyoPhase 2
35
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
35
LenvatinibEisaiPre-clinical
26
LenvatinibEisaiPre-clinical
26
Lenvatinib + Placebo + LenvatinibEisaiPhase 3
40
Irofulven + capecitabineEisaiPhase 2
35
Lenvatinib + PlaceboEisaiPhase 3
40
LenvatinibEisaiApproved
43
LenvatinibEisaiPre-clinical
26
BexaroteneEisaiPhase 1
29
Lenvatinib + Lenvatinib matching placeboEisaiPhase 2
35
LenvatinibEisaiPhase 2
27
LENVATINIBEisaiPhase 2
39
E7080 capsuleEisaiPhase 2
35
Lenvatinib (DTC Cohort) + Lenvatinib (MTC Cohort)EisaiPhase 2
35
KHK7580 + KRN1493Kyowa KirinPhase 2/3
38